Dr. Sofley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2000 E Greenville St
Ste 3850
Anderson, SC 29621Phone+1 864-512-6024Fax+1 864-512-6123
Summary
- Dr. C. Wilson Sofley Jr. is an internal medicine specialist based in Anderson, SC. He completed his residency in internal medicine at Prisma Health/University of South Carolina SOM Columbia in 1989 and earned his medical degree from the University of North Carolina at Chapel Hill School of Medicine in 1986. He has been a partner at Internal Medicine Associates of Anderson since 1993 and previously served as Department Chair at Winn Army Community Hospital. Dr. Sofley has experience in managing hypertension, diabetes mellitus, and hyperlipidemia. His research includes publications in high-impact journals like The New England Journal of Medicine, with notable work on cardiovascular outcomes and atrial fibrillation. He has also been involved in several clinical trials focusing on cardiovascular safety in patients with diabetes. Additionally, he has received specific recognitions such as the CMS Meaningful Use Stage 1 Certification and the Diabetes Recognition Program from the NCQA.
Education & Training
- Prisma Health/University of South Carolina SOM Columbia (Columbia)Residency, Internal Medicine, 1986 - 1989
- University of North Carolina at Chapel Hill School of MedicineClass of 1986
Certifications & Licensure![](https://directory.doximity.com/assets/icons/icon-help-e9f0b148a1e6d1f037dde9f26f025c36bd7c99fd4fe31fd76792996fa2aa5e66.svg)
- SC State Medical License 1987 - 2025
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Practice Fusion EHR, Practice Fusion, Inc., 2012
- Diabetes Recognition Program National Committee for Quality Assurance, 2010-2013
Clinical Trials
- Phase III Acute Coronary Syndrome Start of enrollment: 2009 Mar 01
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Start of enrollment: 2010 Jul 01
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication Start of enrollment: 2010 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsValidating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLO...Wern Yew Ding, Ameenathul Mazaya Fawzy, Giulio Francesco Romiti, Marco Proietti, Daniele Pastori
Journal of Thrombosis and Thrombolysis. 2024-01-01 - 431 citationsSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes.A Michael Lincoff, Kirstine Brown-Frandsen, Helen M Colhoun, John Deanfield, Scott S Emerson
The New England Journal of Medicine. 2023-12-14 - 11 citationsPatterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry.Giulio Francesco Romiti, Bernadette Corica, Marco Proietti, Davide Antonio Mei, Juliane Frydenlund
Eclinicalmedicine. 2023-09-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: